Current Funding Opportunities

Click here to visit the NCI grant site.

Use your device's search function to find a specific disease or funding source. 




Administrative Supplement for Research on Bioethical Issues (PA-19-217) 


The NIH Office of Science Policy (OSP) within the Office of the Director (OD) announces the availability of administrative supplements to support research on bioethical issues to develop an evidence base that may inform future policy directions. Applicants may propose to supplement parent awards focused on bioethics or to add a component related to bioethics to a parent award in which bioethics was not the focus.

Areas of high priority research include, but are not limited to, the bioethical, legal, and societal implications of the following: New and emerging technology development and use; clinical and non-clinical data sharing; precision and personalized medicine; research privacy and security; learning healthcare systems; crowdsourcing; participant-driven research and consumer generated data; patient/participant representation in research oversight; special and vulnerable population research, and more. 

Application Deadline: May 13, 2019, by 5:00 PM local time of applicant organization. 

For additional information about PA-19-217>>


Department of Defense Lung Cancer Research Program

Idea Development Award
 
Established Investigators: Independent investigators at or above the level of Assistant Professor (or equivalent); or
New Investigators: Investigators must meet the following criteria at the application submission deadline date:
• Have not previously received a LCRP Idea Development Award or LCRP Early Investigator Synergistic Idea Award
• Be within 10 years of first faculty appointment (or equivalent)
• Supports new ideas in the early stages of development representing innovative, high-risk/high-gain research.
• Emphasis on innovation and impact.
• New Investigator category supports applicants early in their faculty appointments or in the process of developing independent research careers.
• Clinical trials not allowed.
• Preliminary data required, but may be from outside of lung cancer.
• Relevance Military Health strongly encouraged.

• Maximum funding of $350,000 in direct costs (plus indirect costs).
• Period of performance should not exceed 2 years.

Preproposal Deadline: May 15, 2019


Investigator-Initiated Translational Research Award 
• Independent investigators at or above the level of Assistant Professor (or equivalent)
• Supports translational research that will develop promising ideas in lung cancer into clinical applications. Translational research may be defined as an integration of basic science and clinical observations.
• Intended to fund a broad range of translational studies.
• Clinical trials not allowed.
• Preliminary data required.
• Relevance to Military Health strongly encouraged.

• Maximum funding of $400,000 in direct costs (plus indirect costs).
• Period of performance should not exceed 2 years.

Preproposal Deadline: May 15, 2019


Translational Research Partnership Award 
• Investigators at or above the level of Assistant Professor (or equivalent)
• Supports partnerships between clinicians and research scientists that accelerate ideas in lung cancer into clinical applications.
• One partner is strongly encouraged to be from Department of Defense military treatment facility or laboratory, or Veterans Affairs medical center.
• Clinical trials are allowed.
• Nontraditional Partnerships are encouraged.
• Preliminary data required.
• Relevance to Military Health strongly encouraged.

• Maximum combined funding of $900,000 for direct costs (plus indirect costs).
• Maximum period of performance is 3 years.


Preproposal Deadline: May 15, 2019



Notice of Special Interest: Administrative Supplements for Activities to Promote Human Immune-Representing Oncology Models

Through funds available from the Cancer Moonshot InitiativeSM, and pursuant to the NIH interest in advancing human tissue models that do not rely on human fetal tissue (NOT-OD-19-042), the National Cancer Institute (NCI) is inviting applications for administrative supplements to improve representation of the human immune system in ongoing cancer modeling development projects that can be utilized in immuno-oncology research. Progress for cancer research is highly dependent on the model systems employed. While substantial progress has been made to establish models of increasing complexity to recapitulate aspects of human disease, a critical shortcoming persists for representation of the human immune system in those models. For example, various models can recapitulate key aspects of human T cell immunity but are less able to recapitulate human innate immunity and antibody responses, regardless of the human tissue source. In addition, few direct comparisons have been conducted of mice with humanized immune systems (HIS) derived using fetal vs. non-fetal human tissue sources (https://www.niaid.nih.gov/research/humanized-mouse-model-workshop). HIS mice are used extensively in immuno-oncology research, which is a high priority field of research with support through the Cancer Moonshot Initiative. 

Application Deadline: June 3, 2019

Learn More>>


HEAL Initiative: Early Phase Pain Investigation Clinical Network - Specialized Clinical Centers (U24 Clinical Trial Not Allowed) (RFA-NS-19-036) 

The purpose of this funding opportunity announcement (FOA) is to invite applications for the Specialized Clinical Centers (“hubs”) of the Early Phase Pain Investigation Clinical Network (EPPIC-Net). EPPIC-Net will serve as the cornerstone of the NIH’s Helping to End Addiction Long-term (HEAL) Initiative. EPPIC-Net will provide a robust and readily accessible infrastructure for carrying out in-depth phenotyping and biomarker studies in patients with specific pain conditions, and the rapid design and performance of high-quality Phase 2 clinical trials to test promising novel therapeutics for pain from partners in academia or industry. Studies will bring intense focus to patients with well-defined pain conditions and high unmet therapeutic needs. 

Application Deadline: June 3, 2019 - All types of non-AIDS applications allowed for this funding opportunity announcement are due on this date. No late applications will be accepted for this Funding Opportunity Announcement. 

Learn More>>


Mechanisms Underlying the Contribution of Sleep Disturbances to Pain (R01 Clinical Trial Optional) (PA-19-200)

NCI is a participating organization.

The purpose of this FOA is to encourage mechanistic research to investigate the impact of sleep disturbances on pain. The mechanisms and processes underlying the contribution of sleep and sleep disturbances to pain perception and the development and maintenance of chronic pain may be very broad. This FOA encourages interdisciplinary research collaborations by experts from multiple fields—neuroscientists, psychologists, endocrinologists, immunologists, geneticists, pharmacologists, chemists, physicists, behavioral scientists, clinicians, caregivers, and others in relevant fields of inquiry. Applications proposing to study the impact of pain on sleep will be considered low priority and are unlikely to be funded under this FOA.

Application Deadline: June 5, 2019. 

Learn More>>


Biology of Bladder Cancer (R01/R21)

This FOA encourages applications investigating the biology and underlying mechanisms of bladder cancer.

Application Deadlines: (R01): June 5, 2019 (R21): June 16, 2019



Doris Duke Physician Scientist Fellowship   

The Doris Duke Charitable Foundation (DDCF) has announced the creation of the Doris Duke Physician Scientist Fellowship, an inaugural program now open to clinical investigators currently engaged in subspecialty training. Through the Physician Scientist Fellowship, DDCF will aim to encourage emerging physician scientists to pursue careers in clinical research and hopes to promote their transition into faculty-level positions.  

Application Deadline: June 7, 2019 

Learn more about this fellowship>> 



Modulating Intestinal Microbiota to Enhance Protective Immune Responses against Cancer (R01 Clinical Trial Not Allowed) (PAR-19-198)

The purpose of this Funding Opportunity Announcement (FOA) is to support research which can elucidate mechanism(s) of action by which gut microbes inhibit or enhance anti-tumor immune responses. Thus, research projects should be focused on delineating how specific microbes or their metabolites target host immune responses to prevent colitis-associated or sporadic tumor formation.

Application Deadline: June 10, 2019

Learn More>>



Modulating Intestinal Microbiota to Enhance Protective Immune Responses against Cancer (R21 Clinical Trial Not Allowed) (PAR-19-199)


The purpose of this Funding Opportunity Announcement (FOA) is to support research which can elucidate mechanism(s) of action by which gut microbes inhibit or enhance anti-tumor immune responses. Thus, research projects should be focused on delineating how specific microbes or their metabolites target host immune responses to prevent colitis-associated or sporadic tumor formation. 

Application Deadline: June 10, 2019

Learn More>>


ITCR: innovative algorithms (R21 Clinical Trial Optional) (RFA-CA-19-038)

The purpose of this Funding Opportunity Announcement (FOA) is to invite exploratory/developmental research grant applications (R21) for the development of innovative methods and algorithms in biomedical computing, informatics, and data science addressing priority needs across the cancer research continuum including cancer biology, cancer treatment and diagnosis, early cancer detection, risk assessment and prevention, cancer control and epidemiology, and/or cancer health disparities. As a component of the NCI's Informatics Technology for Cancer Research (ITCR) Program, this FOA encourages applications focused on the development of novel computational, mathematical, and statistical algorithms and methods that can considerably improve acquisition, management, analysis, and dissemination of relevant data and/or knowledge.

Application Deadline: June 11, 2019, by 5:00 PM local time of applicant organization.

Learn More>>


Early-Stage Development of Informatics Technologies for Cancer Research and Management (U01 Clinical Trial Optional) (RFA-CA-19-039)

The purpose of this Funding Opportunity Announcement (FOA) is to invite Cooperative Agreement (U01) applications for the development of enabling informatics technologies to improve the acquisition, management, analysis, and dissemination of data and knowledge across the cancer research continuum including cancer biology, cancer treatment and diagnosis, early cancer detection, risk assessment and prevention, cancer control and epidemiology, and/or cancer health disparities. As a component of the NCI's Informatics Technology for Cancer Research (ITCR) Program, this FOA focuses on early-stage development from prototyping to hardening and adaptation. Early-stage development is defined for the purpose of this FOA as initial tool development or the significant modification of existing tools for new applications.

Application Deadline: June 11, 2019, by 5:00 PM local time of applicant organization. 

Learn More>>


Advanced Development of Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional) (RFA-CA-19-040)

The purpose of this Funding Opportunity Announcement (FOA) is to invite Cooperative Agreement (U24) applications for advanced development and enhancement of emerging informatics technologies to improve the acquisition, management, analysis, and dissemination of data and knowledge across the cancer research continuum including cancer biology, cancer treatment and diagnosis, early cancer detection, risk assessment and prevention, cancer control and epidemiology, and/or cancer health disparities. As a component of the NCI's Informatics Technology for Cancer Research (ITCR) Program, this FOA focuses on emerging informatics technology, defined as one that has passed the initial prototyping and pilot development stage, has demonstrated potential to have a significant and broader impact, has compelling reasons for further improvement and enhancement, and has not been widely adopted in the cancer research field.

Application Deadline: June 11, 2019, by 5:00 PM local time of applicant organization. 

Learn More>>



Sustained Support for Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional) (RFA-CA-19-041)

The purpose of this Funding Opportunity Announcement (FOA) is to invite Cooperative Agreement (U24) applications for the continued development and sustainment of high value informatics research resources to improve the acquisition, management, analysis, and dissemination of data and knowledge across the cancer research continuum including cancer biology, cancer treatment and diagnosis, early cancer detection, risk assessment and prevention, cancer control and epidemiology, and/or cancer health disparities. As a component of the NCI's Informatics Technology for Cancer Research (ITCR) Program, this FOA focuses on sustaining operations and improving the user experience and availability of existing, widely-adopted informatics tools and resources.

Application Deadline: June 11, 2019, by 5:00 PM local time of applicant organization. 

Learn More>>


Mechanisms Underlying the Contribution of Sleep Disturbances to Pain (R21 Clinical Trial Optional) (PA-19-201)

NCI is a participating organization.

The purpose of this FOA is to encourage mechanistic research to investigate the impact of sleep disturbances on pain. The mechanisms and processes underlying the contribution of sleep and sleep disturbances to pain perception and the development and maintenance of chronic pain may be very broad. This FOA encourages interdisciplinary research collaborations by experts from multiple fields—neuroscientists, psychologists, endocrinologists, immunologists, geneticists, pharmacologists, chemists, physicists, behavioral scientists, clinicians, caregivers, and others in relevant fields of inquiry. Applications proposing to study the impact of pain on sleep will be considered low priority and are unlikely to be funded under this FOA.

Application Deadline: June 16, 2019

Learn More>>


Paul Calabresi Career Development Award for Clinical Oncology (K12 Clinical Trial Optional) (PAR-19-242)

The purpose of the Paul Calabresi Career Development Award for Clinical Oncology (PCACO) is to increase the number of clinician-scientists (M.D.s, D.O.s, PharmDs, nurses with PhDs, or equivalent) trained in clinical and translational cancer research, and to promote their career development as cancer researchers. This Funding Opportunity Announcement (FOA) allows appointment of Scholars proposing to serve as the lead investigator of an independent clinical trial; or proposing a separate ancillary clinical trial to an existing trial; or proposing to gain research experience in a clinical trial led by another investigator, as part of their research and career development.

Application Deadline: June 18, 2019

Learn More>>


Optimizing the Management and Outcomes for Cancer Survivors Transitioning to Follow-up Care (R01 Clinical Trial Required) (RFA-CA-19-035)

This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer MoonshotSM Initiative that is intended to accelerate cancer research. This FOA solicits applications that develop and test models of care for adult survivors of cancer who are transitioning from active treatment to follow-up care. Through this FOA, the NCI intends to support multi-level interventions that enhance communication, collaboration, and coordination among oncology and non-oncology providers to improve cancer survivor outcomes.

Application Deadline: June 28, 2019, by 5:00 PM local time of applicant organization. 

Learn More>>


Basic and Translational Research on Adducts in Cancer Risk Identification and Prevention (R01 Clinical Trial Optional) (PAR-19-251)

The overall objective of this Funding Opportunity Announcement (FOA) is to support innovative research on adducts to cellular macromolecules as indicators of exposures to endogenous and exogenous cancer risk factors relevant to exposures in human populations. The priority is on projects that will focus on adductomic approaches, i.e., address some aspects of the totality of adducts. The ultimate goal is to discover and characterize the utility of adductomic-based exposure indicators for cancer detection, cancer prevention, and/or assessing cancer risks. 

Application Deadline: July 2, 2019

Learn More>>



Basic and Translational Research on Adducts in Cancer Risk Identification and Prevention (R21 Clinical Trial Optional) (PAR-19-252) 

The overall objective of this Funding Opportunity Announcement (FOA) is to support innovative research on adducts to cellular macromolecules as indicators of exposures to endogenous and exogenous cancer risk factors relevant to exposures in human populations. The priority is on projects that will focus on adductomic approaches, i.e., address some aspects of the totality of adducts. The ultimate goal is to discover and characterize the utility of adductomic-based exposure indicators for cancer detection, cancer prevention, and/or assessing cancer risks.

Application Deadline: July 2, 2019

Learn More>>



Tobacco Regulatory Science (R01 Clinical Trial Optional)

The purpose of this Funding Opportunity Announcement (FOA) is to invite R01 applications to support biomedical and behavioral research that will provide scientific data to inform regulation of tobacco products to protect public health.

Estimated Application Due Date: July 19, 2019
 




Provocative Questions (PQs) in Cancer with an Underlying HIV Infection (R01 Clinical Trial Optional)

The purpose of this FOA is to continue advancing our understanding of the risks, development, progression, diagnosis, and treatment of malignancies observed in individuals with an underlying HIV infection or AIDS.

Application Deadline: August 1, 2019


The Yale Cancer Center Internal Grant Program aims to provide funds for innovative, high quality start-up cancer research programs and provide new investigators with experience and guidance in the grant-writing process. 

The criteria for funding is high quality, innovative cancer research with a likelihood to result in NIH-funded cancer research and encourage collaborations within YCC. Grant competitions will be announced in DirectConnect and will undergo an anonymous NIH-style peer review with written reviews provided to applicants. 

Current opportunities are listed below. 

View a full list of grant opportunities available throughout the year>> 




2019 Breast Cancer Alliance Young Investigator Award

Purpose: To encourage a commitment to breast cancer research, BCA invites clinical doctors and research scientists whose primary focus is breast cancer and who are in the early stages of their careers to apply for funding for the Young Investigator Grant. This grant is intended to help advance the careers of young researchers who do not yet have their own major grant support.

Eligibility:
• must have held a faculty position for no more than four years following completion of their training, as of February 1, 2020;
• have not been a principal investigator on an NIH R01 or equivalent national/international non-mentored award; and
• dedicate at least 50% of their work effort to research.

For clarity, current postdoctoral fellows who do not yet hold a faculty position are eligible to apply, provided they meet all the other stated criteria for Young Investigators. If you have already submitted an LOI for an Exceptional Project Grant, but were not asked to submit a full proposal, you are ineligible to submit the same proposal for a Young Investigator Grant.

Internal Application Deadline: June 4, 2019

Learn More and Apply>>



Luminary Award of Excellence

The YNHH Smilow Luminary Award of Excellence will serve to recognize, and ceremoniously acknowledge, those individuals and/or teams who consistently exceed performance expectations and deliver high quality cancer care for our patients, families and the health system through community service, optimization/ innovative solutions, patient experience, leadership and research initiatives. Nominations should be submitted directly to  Luminary@ynhh.org